TY - JOUR
T1 - Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma
AU - Noda, Teppei
AU - Komune, Noritaka
AU - Yasumatsu, Ryuji
AU - Tsuchihashi, Nana Akagi
AU - Tamae, Akihiro
AU - Matsumoto, Nozomu
AU - Sato, Kuniaki
AU - Uchi, Ryutaro
AU - Koike, Kensuke
AU - Wakasaki, Takahiro
AU - Tanaka, Risa
AU - Nakagawa, Takashi
N1 - Funding Information:
We thank Prof. Brian Quinn for the proof-reading support. This research was funded by JSPS KAKENHI Grant JP17K16925 (TNo) and JP18H02951 (TNa).
Publisher Copyright:
© 2020
PY - 2020/10
Y1 - 2020/10
N2 - Objective: The immune checkpoint inhibitor Nivolumab was approved for the treatment of platinum-refractory head and neck squamous cell carcinoma (SCC), expanding the treatment options for recurrent or advanced head and neck SCC. However, since temporal bone squamous cell carcinoma (TB-SCC) is very rare cancer, the effectiveness of Nivolumab remains unclear. We investigated the effects of Nivolumab for TB-SCC. Method: Chart information was collected for all patients who underwent the first administration of Nivolumab for recurrent or residual TB-SCC in our hospital between September 2017 and December 2019. Tumor staging followed the modified Pittsburgh classification. Changes in the tumor burden and survival outcome were examined. Results: We examined 9 patients with recurrent or residual TB-SCC who started administration of Nivolumab. In these cases, recurrent or residual SCC was observed after chemotherapy and/or chemoradiotherapy including platinum. The duration of Nivolumab was 2–54 weeks (median 20.0 weeks). The evaluation of the therapeutic effect according to the RECIST method showed partial response in 1 case, stable disease in 2 cases, progressive disease in 4 cases, and size unevaluated in 2 case. Although the number of cases was small, comparing with 5 cases without Nivolumab, these cases showed longer overall survival (1-year OS 33.3% vs 20.0%). Conclusion: We used Nivolumab as palliative chemotherapy in 9 patients with recurrent/residual TB-SCC, and we were able to obtain a certain therapeutic effect on TB-SCC as well as other head and neck SCC.
AB - Objective: The immune checkpoint inhibitor Nivolumab was approved for the treatment of platinum-refractory head and neck squamous cell carcinoma (SCC), expanding the treatment options for recurrent or advanced head and neck SCC. However, since temporal bone squamous cell carcinoma (TB-SCC) is very rare cancer, the effectiveness of Nivolumab remains unclear. We investigated the effects of Nivolumab for TB-SCC. Method: Chart information was collected for all patients who underwent the first administration of Nivolumab for recurrent or residual TB-SCC in our hospital between September 2017 and December 2019. Tumor staging followed the modified Pittsburgh classification. Changes in the tumor burden and survival outcome were examined. Results: We examined 9 patients with recurrent or residual TB-SCC who started administration of Nivolumab. In these cases, recurrent or residual SCC was observed after chemotherapy and/or chemoradiotherapy including platinum. The duration of Nivolumab was 2–54 weeks (median 20.0 weeks). The evaluation of the therapeutic effect according to the RECIST method showed partial response in 1 case, stable disease in 2 cases, progressive disease in 4 cases, and size unevaluated in 2 case. Although the number of cases was small, comparing with 5 cases without Nivolumab, these cases showed longer overall survival (1-year OS 33.3% vs 20.0%). Conclusion: We used Nivolumab as palliative chemotherapy in 9 patients with recurrent/residual TB-SCC, and we were able to obtain a certain therapeutic effect on TB-SCC as well as other head and neck SCC.
UR - http://www.scopus.com/inward/record.url?scp=85085057213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085057213&partnerID=8YFLogxK
U2 - 10.1016/j.anl.2020.03.011
DO - 10.1016/j.anl.2020.03.011
M3 - Article
C2 - 32446629
AN - SCOPUS:85085057213
SN - 0385-8146
VL - 47
SP - 864
EP - 869
JO - Auris Nasus Larynx
JF - Auris Nasus Larynx
IS - 5
ER -
